Open AccessSIRT7 restricts HBV transcription and replication through catalyzing desuccinylation of histone H3 associated with cccDNA minichromosome
Author(s) -
Haibo Yu,
Sheng-Tao Cheng,
Fang Ren,
Yong Chen,
Xiaofeng Shi,
Vincent Kam Wai Wong,
Betty Yuen Kwan Law,
Ji-Hua Ren,
Sen Zhong,
Weixian Chen,
Hong Xu,
Zhen Zhen Zhang,
Jie Hu,
Xue Cai,
Yuan Hu,
Wen Lu Zhang,
Quanxin Long,
Lin He,
Zhong Wen Hu,
Hui Jiang,
Hong Zhou,
Aiping Huang,
Juan Chen
Publication year - 2021
Publication title -
clinical science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.91
H-Index - 138
eISSN - 1470-8736
pISSN - 0143-5221
DOI - 10.1042/cs20210392
Subject(s) - cccdna , minichromosome , biology , histone , histone h3 , microbiology and biotechnology , chromatin , hepatitis b virus , cancer research , virology , genetics , virus , gene , hbsag
Chronic hepatitis B virus (HBV) infection is a significant public health burden worldwide. HBV covalently closed circular DNA (cccDNA) organized as a minichromosome in nucleus is responsible for viral persistence and is the key obstacle for a cure of chronic hepatitis B (CHB). Recent studies suggest cccDNA transcription is epigenetically regulated by histone modifications, especially histone acetylation and methylation. In the present study, we identified transcriptionally active histone succinylation (H3K122succ) as a new histone modification on cccDNA minichromosome by using cccDNA ChIP-Seq approach. Silent mating type information regulation 2 homolog 7 (SIRT7), as an NAD+-dependent histone desuccinylase, could bind to cccDNA through interaction with HBV core protein where it catalyzed histone 3 lysine 122 (H3K122) desuccinylation. Moreover, SIRT7 acts cooperatively with histone methyltransferase, suppressor of variegation 3–9 homolog 1 (SUV39H1) and SET domain containing 2 (SETD2) to induce silencing of HBV transcription through modulation of chromatin structure. Our data improved the understanding of histone modifications of the cccDNA minichromosome, thus transcriptional silencing of cccDNA may represent a novel antiviral strategy for the prevention or treatment of HBV infection.